Hormonal
Once-weekly subcutaneous semaglutide at 2.4 mg is effective and safe for weight loss in non-diabetic adults and adolescents with overweight or obesity, demonstrating superiority over both placebo and daily liraglutide.
For non-diabetic adults and adolescents with obesity, once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle changes is a highly effective treatment for significant weight loss. It is superior to placebo and daily liraglutide. While gastrointestinal side effects like nausea are common, they often subside over time. This treatment is FDA-approved and supported by robust clinical trials.
Os artigos expostos neste estudo serviram para consolidar a segurança e eficácia do uso de semaglutida subcutânea na dose de 2,4 mg em pacientes não diabéticos, com o intuito de promover o emagrecimento e diminuição do risco cardiometabólico. Essa medicação se mostrou superior a placebo e a outro agonista de GLP-1, a liragutida.
Why this rating
The paper synthesizes multiple high-quality Randomized Clinical Trials (RCTs) including STEP 1, 3, 4, 5, 8, and STEP TEENS, published in major journals (NEJM, JAMA, Nature Medicine).
Source
Semaglutida no tratamento de obesidade e sobrepeso
Izadora Pires de Oliveira et al. · Research Society and Development · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →